What Urgo Medical does

Urgo Medical is the advanced wound care division of the French family-owned Urgo Group, operating in the Netherlands through Urgo Nederland B.V. (headquartered at Laarderhoogtweg 25, 1101 EB Amsterdam). The company develops and markets a portfolio of nine branded medical devices — UrgoTul, UrgoTul Ag, UrgoClean, UrgoClean Ag, UrgoStart Contact, UrgoStart Plus Pad, UrgoStart Plus Border, UrgoK2, and UrgoK2 Lite — organized around four technology platforms: Lipido-Colloid (TLC) wound contact layers, poly-absorbing fiber cleansers, TLC-NOSF healing matrices, and multi-component compression systems. Products target healthcare professionals (nurses, wound care specialists, podiatrists, doctors) treating venous leg ulcers, diabetic foot ulcers, pressure ulcers, burns, surgical wounds, traumatic wounds, and epidermolysis bullosa.

The technological foundation rests on three patented Lipido-Colloid platforms developed by parent Les Laboratoires Urgo (Chenôve, France): the base TLC matrix combining carboxymethylcellulose, paraffin, and petrolatum into a moist-healing gel; TLC-Ag incorporating silver ions for antimicrobial action against MRSA and biofilm-forming organisms; and TLC-NOSF (potassium octasulfate sucrose salt), which targets excess Matrix Metalloproteinases to reduce chronic wound healing time. Clinical validation includes the EXPLORER randomized controlled trial (The Lancet, December 2018) and the REALITY analysis of more than 10,000 patients (Journal of Wound Care, 2017), with claimed outcomes of a 100-day average reduction in chronic wound healing time and 60% more patients healed versus neutral dressings. The PressSure visual pressure indicator system supports consistent therapeutic compression (40 mmHg / 20 mmHg) with first-application accuracy rates of 85% among nurses. Regulatory endorsements include NICE (UK, 2019, revised 2023), IWGDF guidelines (2019, first wound dressing so recommended), HAS CAV III clinical added value (France), and the 2018 Galien France Medical Devices Prize.

Urgo Medical generates revenue through medical device hardware sales, with products distributed via healthcare medical supply channels to hospitals, wound care clinics, and community care settings in the Netherlands, with international reach extending across Europe, Asia, and North and South America through parent Urgo Group (approximately 1,500–1,600 employees globally). The go-to-market is enterprise field sales-led, executed through dedicated product specialist meetings, clinical training programs, and trade show participation; pricing is determined through institutional procurement processes and is not publicly disclosed. A strategic GTM partnership with the NHS in the UK (GO75 initiative, 2023) extends clinician engagement into public-sector wound care delivery.

Name

Urgo Medical

Legal name

Urgo Nederland B.V.

Website

https://urgomedical.nl

Company type

Private

Operating status

Operating

Headcount range

51–100 employees

Short description

Urgo Medical is the advanced wound care division of French family-owned Urgo Group, operating in the Netherlands through Urgo Nederland B.V. The company develops and distributes proprietary Lipido-Colloid technology wound dressings, antimicrobial products, and multi-component compression systems to healthcare professionals treating chronic and acute wounds.

Ownership category

akta.pro rank

Product category

Advanced Wound Care Medical Devices

NAICS

Surgical and Medical Instrument Manufacturing (339112), Surgical Appliance and Supplies Manufacturing (339113)

SIC

Surgical & Medical Instruments & Apparatus (3841), Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)

akta.pro primary industry

Skin Substitutes & Biologic/Regenerative Wound Therapies (Matrices, Grafts) (HLAHALAE)

akta.pro secondary industries

Antimicrobial Wound Care (Silver/Iodine/PHMB Dressings, Wound Irrigation) (HLAHALAC), Compression Therapy & Lymphedema DME (Garments, Pneumatic Pumps) (HLAHAMAH)

Keywords

• Advanced wound care
• Medical wound dressings
• Compression therapy systems
• Chronic wound treatment
• Wound healing technology

Headquarters

HQ city

Amsterdam

HQ country

Netherlands

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Supply Chain, Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

1. Medical Device Sales (Advanced Wound Care Products): Urgo Medical generates revenue through the sale of advanced wound care medical devices including compression systems (UrgoK2, UrgoK2 Lite), wound contact layers (UrgoTul, UrgoTul Ag), antimicrobial dressings (UrgoClean Ag), and advanced healing matrices (UrgoStart Plus Pad, UrgoStart Plus Border, UrgoStart Contact). Products are supplied to healthcare professionals and institutions through medical supply channels.

Go-to-market motion2 records

Distribution channels1 record

Marketing channels5 records

Core offering

Urgo Medical develops, manufactures, and sells advanced wound care medical devices, including Lipido-Colloid Technology (TLC) wound contact layers, TLC-NOSF healing matrices, antimicrobial silver dressings (TLC-Ag), poly-absorbing fiber wound cleaners, and multi-component compression systems for venous leg ulcers. The products are designed for healthcare professionals to treat chronic and acute wounds such as leg ulcers, diabetic foot ulcers, pressure ulcers, burns, and surgical wounds.

Product overview

Urgo Medical is the advanced wound care division of the French Urgo Group, offering a comprehensive portfolio of wound care products designed for healthcare professionals to treat both acute and chronic wounds. The product portfolio is organized around several core technology platforms: UrgoTul (Lipido-Colloid Technology dressings for wound contact), UrgoClean (hydro-cleaning polyabsorbing fibers for wound preparation), UrgoStart (TLC-NOSF technology addressing wound healing factors), and UrgoK2 (multi-component compression systems). These products address various wound types including venous leg ulcers, diabetic foot ulcers, pressure ulcers, burns, surgical wounds, and traumatic wounds. The company emphasizes evidence-based treatments with clinical research supporting product efficacy.

Differentiator

Problem solved

Functional benefit

Brands

• UrgoK2: Multicomponent compression system for venous leg ulcers, venous edema and lymphedema providing 40 mmHg therapeutic pressure
• UrgoK2 Lite
• UrgoClean Ag
• UrgoClean
• UrgoStart Contact
• UrgoStart Plus Pad
• UrgoStart Plus Border
• UrgoTul
• UrgoTul Ag

Products and services

• UrgoTul A non-adhesive, non-occlusive wound contact layer using proprietary Lipido-Colloid (TLC) technology. Creates a moist wound environment promoting healing without adhering to the wound bed, enabling pain-free and atraumatic dressing changes. Indicated for acute wounds (burns, traumatic wounds, surgical wounds) and chronic wounds (pressure ulcers, diabetic foot ulcers) during granulation and epithelialization phases.
• UrgoTul Ag A non-adhesive wound contact layer with TLC-Ag (silver) matrix providing antibacterial action effective against MRSA, VRE, and a broad spectrum of microorganisms. Indicated for wounds with risk of infection or signs of local infection including burns, traumatic wounds, surgical wounds, lower limb wounds, diabetic foot wounds, and pressure ulcers.
• UrgoClean Ag Anti-biofilm silver dressing combining poly-absorbing fibers with TLC-Ag matrix. Destroys and removes biofilm while preventing reformation for up to 7 days. Reduces 99.99% of biofilm within 24 hours (in-vitro studies on S. aureus and P. aeruginosa). Indicated for all wounds with (risk of) local infection such as leg ulcers, diabetic foot ulcers, pressure ulcers, burns, abrasions, traumatic wounds, and post-operative wounds.
• UrgoClean Wound preparation dressing that safely and effectively removes dirt and debris. Features hydro-cleaning poly-absorbing fibers with high absorption capacity that bind and remove exudate, debris, and slough while maintaining autolytic debridement. Indicated for exuding wounds in the cleaning phase (chronic and acute wounds); UrgoClean Rope variant used for deep cavitary wounds.
• UrgoStart Contact A non-adhesive, non-occlusive contact layer with TLC-NOSF (Lipido-Colloid Nano-OligoSaccharide Factor) matrix. Reduces healing time by addressing excess Matrix Metalloproteinases (MMPs). Indicated for patients with leg ulcers, diabetic foot ulcers, and pressure ulcers from the moment granulation tissue appears until complete healing.
• UrgoStart Plus Pad A dressing indicated for all healing phases (from debridement phase to healing) for treatment of chronic exuding wounds (leg ulcers, pressure ulcers, diabetic foot ulcers) and acute wounds that have become chronic. Features TLC-NOSF Healing Matrix and poly-absorbing fibers that reduce healing time by an average of 100 days. NICE recommended for diabetic foot ulcers and venous leg ulcers.
• UrgoStart Plus Border A bordered dressing for all healing phases (from debridement to healing) for all leg ulcers, pressure ulcers, diabetic foot ulcers, and non-healing acute wounds. Features TLC-NOSF matrix reducing excess MMPs and poly-absorbing fibers providing continuous wound cleansing. Reduces healing time by an average of 100 days. NICE recommended.
• UrgoK2 Multi-component compression system consisting of a short-stretch padding bandage and a long-stretch cohesive bandage achieving therapeutic pressure of 40 mmHg at the ankle. Designed for venous leg ulcers, venous edema, and lymphedema. Features the PressSure system for consistent therapeutic pressure from first treatment.
• UrgoK2 Lite Multi-component compression system achieving lower therapeutic pressure of 20 mmHg at the ankle. Consists of K-Tech (short-stretch) and K-Press (long-stretch) layers. Designed for venous leg ulcers, venous edema, and lymphedema where lower compression is recommended. Features the PressSure system for consistent pressure delivery.

Quantifiable outcome

• TLC-NOSF treatment reduces chronic wound healing time by an average of 100 days (REALITY analysis of 10,000+ patients, Journal of Wound Care 2017).
• +6 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles2 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature5 records

Partnerships

One partnership is on record.

• NHS (National Health Service, UK)coreGTM or Marketing Partner · 1 January 2023Urgo Medical partnered with the NHS for the GO75 initiative celebrating the NHS's 75th anniversary in July 2023. Urgo Medical staff across the UK support NHS clinicians in wound healing efforts. The GO75 initiative brought educational team meetings and community project support to NHS teams, with nominated community projects receiving support from the GO75 team.

Scale indicators3 records

Recent moves6 records

Expansion highlights5 records

Emerging players

• MiMedx: US-listed regenerative medicine company (EpiFix, AmnioFix) focused on amniotic tissue and skin substitute products for chronic wounds. Emerging competitor to Urgo Medical's TLC-NOSF in the diabetic foot ulcer and venous leg ulcer niches.
• Organogenesis Holdings: US-listed regenerative medicine company focused on advanced wound care (Apligraf, Dermagraft) and surgical biologics. Comparable in clinical positioning around biologic and matrix-based wound healing, and a relevant competitor in the diabetic foot ulcer / venous leg ulcer segments where Urgo Medical's TLC-NOSF is recommended.

Regional players

• Hartmann Group: German family-owned medical and hygiene products company with a Wound Management division (Hydrocoll, PermaFoam, Atrauman). Comparable mid-sized European player with overlapping dressing portfolio and a similar family-ownership governance structure.

Broad incumbents

• Coloplast: Danish medical device company with a Wound & Skin Care business (Biatain, Comfeel) plus dominant ostomy and continence franchises. Competes directly with Urgo Medical in advanced wound dressings and shares the Scandinavian / Northern European institutional customer base.
• Integra LifeSciences: US-listed medical technology company with a dedicated Tissue Technologies / Wound Care portfolio (Integra Dermal Regeneration Template, PriMatrix, AmnioExcel). Comparable in regenerative wound healing focus and a relevant competitor in the skin substitute / biologic dressing category.
• Smith+Nephew: Global medical device major with a sizable Advanced Wound Management franchise (ALLEVYN, PICO NPWT, IODOSORB). Directly competes with Urgo Medical across antimicrobial dressings, foam dressings, and negative pressure wound therapy, with far larger scale and a multi-specialty portfolio.
• B. Braun: German family-owned medical device and pharmaceutical company with wound care products (Askina, Cosmopor). Competes with Urgo Medical across hospital-based wound care and shares a comparable Central European DACH-channel strength.
• 3M Health Care (Solventum): Now operating as Solventum following spin-off, 3M's Health Care business is a broad incumbent in advanced wound care (Tegaderm, Cavilon) with global distribution that competes with Urgo Medical across acute and chronic wound dressings.

Direct peers

• Mölnlycke Health Care: Swedish-headquartered pure-play wound care and surgical solutions company (Mepilex, Mepitel, Exufiber). Closest direct comparable to Urgo Medical: similar advanced wound dressing focus, comparable European heritage, and overlapping hospital and community-care customer base.
• ConvaTec: UK-listed medical products company with a leading Advanced Wound Care franchise (Aquacel, Foam Lite, DuoDERM). Direct competitor in chronic wound dressings with comparable NICE / NHS engagement depth and a substantially larger commercial footprint.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat3 records

Key risks5 records

Key highlights6 records

Customer concentration

• YouTubeyoutube.com/@urgonederland1970
• LinkedInlinkedin.com/company/urgo-medical

Revenue estimate

Valuation estimate

Number of profiles

Profiles1 record

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Urgo Medical